Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × gadoteridol × Clear all
NCT02359097 2022-03-17

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

OHSU Knight Cancer Institute

Phase NA Completed
29 enrolled
CNS

Glioblastoma

NCT03750188 2020-01-23

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

Bracco Diagnostics, Inc

Completed
125 enrolled
CNS

Central Nervous System Diseases, Central Nervous System Neoplasms

NCT00522951 2017-08-28

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Bayer

Phase 3 Completed
165 enrolled 24 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡